Astellas Pharma Inc. (ALPMF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Tokyo, Japan. Der aktuelle CEO ist Naoki Okamura.
ALPMF hat IPO-Datum 2010-04-26, 14,754 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $29.61B.
Astellas Pharma Inc. is a Japan-based pharmaceutical company founded in 1923 that manufactures, markets, and distributes medicines globally across oncology, urology, immunology, and infectious disease. The company's key products include XTANDI for prostate cancer, XOSPATA for acute myeloid leukemia, PADCEV for urothelial cancer, Myrbetriq for overactive bladder, Evrenzo for anemia in chronic kidney disease, and Prograf for transplant immunosuppression. Astellas maintains an extensive pipeline and strategic partnerships with leading institutions including Merck, Harvard University, and CytomX Therapeutics, as well as collaborations in emerging areas such as targeted radiotherapy, cell therapy, and epigenetic research. The company is headquartered in Tokyo and operates a diversified portfolio of prescription and specialty pharmaceutical products serving major markets worldwide.
